MedLife, the largest private healthcare network in Romania, announces its financial results for the first half of 2025. The Group reported a pro-forma consolidated turnover of RON 1.57 billion, up 20.3 percent compared to the same period in 2024, and a pro-forma EBITDA of RON 234 million, 21.2 percent above the level recorded last year.

The growth was mainly supported by the hospital division, which registered a 38 percent advance, thanks to the recent investments in robotic surgery and the expansion of the range of surgical interventions especially in niche areas.

In addition to the hospital network, the laboratories reported an increase of 18 percent, while the clinic division reported an increase of 20 percent due to the constant interest in high-performance imaging services.

“Our priorities in the first half of the year were focused on increasing operational activity in the recently acquired units and those inaugurated in 2024, as well as on the organic development of the entire Group, in a market with a moderate growth rate, as well as a less friendly macroeconomic environment. However, we have demonstrated that our growth engines work even in these conditions. We are confident that, with the implementation of the new reforms, the economy will gradually resume its growth trajectory, especially starting from mid-2026. Until then, however, we are ready to face the macroeconomic challenges, keeping patient needs at the center of our actions and the determination to constantly innovate and strengthen our status as a medical technology company”  said Mihai Marcu, President and CEO of MedLife Group.

MedLife has accelerated strategic investments in genetics and artificial intelligence, two directions that will fundamentally transform the medicine of the future. Thus, in the first half of the year, the company invested EUR 3 million in the acquisition of Illumina NovaSeq X Plus, the most advanced sequencing technology in the world, preparing the launch of a large-scale genetic testing program. The initiative aims to democratize genetic testing in Romania and move to a proactive approach to medicine, based on accurate data and prevention.

In the medium and long term, the company aims to accelerate and diversify genetic testing and sequencing projects, expand artificial intelligence programs and strengthen the prevention, nutrition and wellness segments.